On Monday, Jefferies revised its financial outlook on Teladoc Health Inc (NYSE:TDOC), reducing the stock price target to $14.00 from the previous $16.00 while maintaining a Hold rating. The adjustment follows the evaluation of the company's first-quarter results and the latest guidance provided by its management. The firm has moderated its expectations for Teladoc's BetterHelp business, noting that year-over-year comparisons are showing a negative trend.
The firm's analyst stated that the updated model takes into account the recent quarterly performance and comments from the management team. As a result, the revenue and EBITDA forecasts for the fiscal years 2024 through 2026 have been revised.
The new projections for revenue are now set at $2,625 million for 2024, $2,724 million for 2025, and $2,798 million for 2026. Similarly, the EBITDA estimates have been adjusted to $362 million for 2024, $393 million for 2025, and $414 million for 2026.
These updated figures represent a decrease from the previous estimates, which had the revenue at $2,671 million for 2024, $2,738 million for 2025, and $2,794 million for 2026, with EBITDA at $367 million for 2024, $391 million for 2025, and $409 million for 2026. The changes reflect a more conservative outlook for the company's performance over the next few years.
The analyst reiterated the Hold rating on Teladoc shares, suggesting that investors maintain their current positions without increasing or decreasing their stake in the company. The revised price target and financial estimates are based on the latest available data and the firm's analysis of the company's business trajectory.
Teladoc Health Inc, listed on the New York Stock Exchange, is a telemedicine and virtual healthcare company. It has been closely watched by investors as the telehealth sector experiences shifts in consumer behavior and regulatory environments. The updated guidance from Jefferies provides a current perspective on the company's financial health and market position.
InvestingPro Insights
As Teladoc Health Inc (NYSE:TDOC) navigates through a challenging period, real-time data from InvestingPro offers additional context to Jefferies' revised financial outlook. The company's market capitalization stands at $2.11 billion, reflecting its current valuation in the market.
Despite the downward revision of earnings by analysts, Teladoc's valuation implies a strong free cash flow yield, suggesting potential for investor returns. Still, it is critical to note that analysts do not expect the company to be profitable this year, which is an important consideration for investors.
On a positive note, Teladoc's liquid assets surpass its short-term obligations, indicating a degree of financial flexibility. Yet, the firm is trading near its 52-week low and has not been profitable over the last twelve months, factors that might concern investors looking for immediate profitability.
Moreover, the stock has seen a significant price drop over the last three months, which could either signal a buying opportunity for value investors or a red flag for those wary of declining stock performance.
Investors interested in a deeper analysis can find more InvestingPro Tips on Teladoc, including insights on EBITDA valuation multiples and dividend policies. For those looking to leverage these insights, InvestingPro offers additional tips—more than eight for Teladoc alone. To enrich your investment decision-making, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.